Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that familiar routine of deadlines, meetings, and the like has returned. You knew this would happen, yes? To cope, as always, we are heating cups of stimulation in the coffee kettle and invite you to join us. And why not? A prescription is not required. Meanwhile, here are some tidbits. Have a lovely day and keep in touch …
Merck agreed to pay $625 million to Bristol-Myers Squibb and Ono Pharmaceutical to settle patent litigation over its Keytruda PD-1 cancer treatment. Bristol-Myers Squibb and Ono claimed that Keytruda sales infringed on their own PD-1 patents, which underpin the Opdivo treatment. Merck will also pay royalties on global Keytruda sales of 6.5 percent between 2017 and the end of 2023, and 2.5 percent between 2024 and 2026.
About the Author Reprints
